Prostate cancer is an extremely common disease that affects one out of every seven men in their lifetime. Our laboratory works to better understand the molecular underpinnings of prostate cancer to develop more effectively treat this common disease.
Many congratulations to Flora Huang for being awarded the 2021 Co-op Supervisor Awards for being one of the top mentors among hundreds of Co-op employers! Very well deserved. Also thanks to Kevin Xiao for being a fantastic Co-op student.
Şeref, C., Acar, Ö., Kılıç, M., Vural, M., Sağlıcan, Y., Saraç, H., Coşkun, B., İnce, Ü., Esen, T., & Lack, N. A. (2021). Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations. The Prostate. doi: 10.1002/pros.24255
Leblanc, E., Ban, F., Cavga, A. D., Lawn, S., Huang, C. F., Mohan, S., Chang, M., Flory, M. R., Ghaidi, F., Lingadahalli, S., Chen, G., Yu, I., Morin, H., Lallous, N., Gleave, M. E., Mohammed, H., Young, R. N., Rennie, P. S., Lack, N. A., & Cherkasov, A. (2021). Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry. doi: 10.1021/acs.jmedchem.1c00681